Tesla’s “Terafab” semiconductor ambitions to launch this week carry an estimated price tag of $25-40 billion. The math is getting hard to reconcile with a company that generated just $6.2 billion in free cash flow last year while its earnings crashed.
Tesla hasn’t raised capital through a stock offering since December 2020, when it completed the last of three at-the-market offerings that brought in roughly $12 billion in a single year. The Terafab changes the equation entirely.
The cash flow problem
Tesla ended 2025 with $44.06 billion in cash and investments, a substantial war chest, but one that’s about to face unprecedented demands. The company’s 2026 capital expenditure guidance of over $20 billion represents more than a doubling of the $8.53 billion it spent in 2025. Tesla’s own 10-K filing states that heightened capex “will necessitate additional funding beyond our operating cash flow.”
The concerning part is the trajectory. Tesla’s full-year 2025 revenue declined 3% to $94.8 billion, with automotive revenue, still the core business, down 10% to $69.5 billion. Net income fell 46% to $3.79 billion. Operating margin collapsed from 7.2% to 4.6%. Free cash flow came in at $6.2 billion for the full year ($14.75 billion in operating cash flow minus $8.53 billion in capex).
If Tesla’s operating cash flow remains anywhere near flat,and there’s no obvious catalyst for a dramatic improvement given declining automotive revenue, then $20 billion in capex alone would push the company to roughly negative $5 billion in free cash flow for 2026. That would burn through over 11% of its cash reserves in a single year, before the Terafab even breaks ground.
And then there’s Terafab
The $20 billion capex guidance doesn’t yet fully account for the Terafab. Musk announced last week that the “Terafab Project launches in 7 days,” targeting a 2nm semiconductor fabrication facility that would manufacture AI chips for Tesla’s self-driving systems, Cybercab robotaxis, and Optimus robots.
For context, Samsung’s single fab in Taylor, Texas cost roughly $17 billion. TSMC’s largest “Gigafab” facilities cost $15-20 billion each and handle about 100,000 wafer starts per month. Musk envisions a facility that would eventually dwarf those, despite Tesla having zero semiconductor manufacturing experience.
Musk’s ‘Tera-scale’ is vague, but he implies that it will be much bigger than TSMC’s ‘Gigafab’. Even assuming that Tesla finds cost efficiencies, the estimated cost of Tesla’s Terafa is between $25 billion and $40 billion.
Even if the Terafab spend is spread over several years, the company would need operating cash flow to nearly double just to break even on a free cash flow basis. Nothing in Tesla’s current financial trajectory suggests that’s coming.
Tesla’s capital raise history
Tesla has gone over five years without selling stock — the longest stretch in its history as a public company. The last time Tesla raised capital was in December 2020, when it completed a $5 billion at-the-market offering. That was the third such raise of the year: $2.3 billion in February, $5 billion in September, and $5 billion in December — roughly $12 billion total.
At the time, Musk had insisted just weeks before the February offering that raising capital “doesn’t make sense,” only to reverse course. The $12 billion raised in 2020 funded Giga Texas and other expansion projects.
The 2020 raises came when Tesla’s market cap was surging past $600 billion, a convenient moment to sell shares at historically high valuations. Today, Tesla’s market cap hovers around $1.5 trillion depending on the day, with a stock that’s been under pressure from declining fundamentals and the political controversy surrounding Musk’s role in the Trump administration.
The setup for a secondary offering
The pieces are falling into place for Tesla’s first capital raise since 2020. Consider the factors converging:
Tesla is guiding $20 billion+ in capex for 2026, and its own 10-K explicitly states the company “may decide it is best to raise additional capital or seek alternative financing sources to fund the rapid growth of our business.” The Terafab adds another $25 billion in projected costs over the coming years. Automotive revenue and margins are declining, not growing. Free cash flow is on a trajectory toward negative territory even without the Terafab. And Tesla’s stock, while far below its peak, still carries a valuation premium that makes equity issuance attractive compared to debt.
An at-the-market offering, the mechanism Tesla used in 2020, would allow the company to sell shares gradually at prevailing market prices, minimizing the one-day stock impact. At current share prices, Tesla could raise $10-15 billion by diluting shareholders just 1-2%, which would barely register in the company’s massive float.
Electrek’s Take
We think a capital raise is not just possible, it’s essentially inevitable given what Tesla is trying to do. The numbers simply don’t work otherwise.
Tesla generated $6.2 billion in free cash flow in 2025 with $8.53 billion in capex. Now it’s promising $20 billion+ in capex for 2026 and it’s going to start work on a $25-40 billion chip fab. Even if the Terafab spend ramps gradually, the combined investment demands over the next 3-5 years likely exceed $80-100 billion. Tesla’s existing cash pile and operating cash flow can’t sustain that without either a dramatic revenue acceleration, difficult when your core car business is shrinking, or external capital.
The truth is that Tesla was heading toward a capital raise no matter what. It has shrinking profits, and its stock price hasn’t suffered much from it. Tesla is literally heading toward negative cash flow in 2026 purely from a shrinking auto business. The Terafab simply gives Tesla an excuse to raise capital for future growth rather than looking like a business about to turn negative.
Furthermore, a company valued at $1.5 trillion and barely making $6 billion in free cash flow would be mad not to tap the public market.
The irony is that Musk resisted capital raises for years, insisting they weren’t necessary, only to raise $12 billion in 2020 when the opportunity presented itself. The stock’s current valuation creates a similar window. A $10-15 billion at-the-market offering would barely dent the share count while providing the runway Tesla needs for its most ambitious industrial project yet.
The question isn’t whether Tesla will raise capital, it’s when and how much. The Terafab announcement may have just accelerated that timeline considerably.
FTC: We use income earning auto affiliate links. More.
Comments